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Case Report
After meningioma, glioblastoma multiforme is the 
most common tumor of the central nervous system 
(CNS). Median survival of patients with newly di-
agnosed glioblastoma is approximately 10 months 
(1). Standard therapy consists of surgical resection 
followed by radiotherapy. Consolidation chemo-
therapy is usually applied to patients with good per-
formance status, but survival benefit is minimal.
Recently, a statistically significant survival im-
pact has been obtained by adjuvant and concom-
itant administration of temozolomide with ex-
ternal radiotherapy (2). Nevertheless, significant 
survival benefit was seen only in particular groups 
of patients, those with methylated O6-methylgua-
nine-DNA methyltransferase (MGMT) gene pro-
moter (3). In the event of disease progression, af-
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We describe the response to a new chemotherapy agent, topoisom-
erase I inhibitor edotecarin in an 18-year-old woman with recurring 
glioblastoma. The therapy was administered for 17 months. The radio-
logical partial response and clinical improvement have been achieved, 
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is 10 months. With edotecarin we have achieved promising result, 
which should encourage further investigations to develop more effi-
cient therapy for such a deadly disease.
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ter radiotherapy and first-line chemotherapy, 
there is no standard treatment available. If ni-
trosourea-based chemotherapy is adjuvantly ap-
plied, second-line monotherapy with temozolo-
mide is usually given with modest clinical efficacy 
(4,5). According to these clinical facts, it is obvi-
ous that more successful treatment regimens are 
required.
Edotecarin is a new indolocarbazole, a potent 
inhibitor of topoisomerase I (6). In comparison 
with other topoisomerase inhibitors, especially 
with derivatives of camptothecin, it has a broad 
spectrum of antitumor activity, a wider thera-
peutic index in preclinical models, and longer du-
ration of action. It also seems to interact with the 
enzyme in a different manner. Also, unlike deriv-
atives of camptothecin, edotecarin is active with-
out metabolic conversion. In vitro studies have 
shown activity of edotecarin against some mul-
tidrug-resistant cell lines, and synergistic or ad-
ditive effects in combination with other chemo-
therapeutic agents.
In vivo studies confirmed the synergistic ef-
fect of edotecarin in combination with both cis-
platin and etoposide. Also, edotecarin was test-
ed on a panel of malignant CNS tumor-derived 
xenografts growing subcutaneously and intra-
cranially in nude mice. It demonstrated statis-
tically significant antitumor activity against all 
xenografts tested in the subcutaneous site and 
produced an 83% increase in survival in mice 
bearing intracranial (D-456MG) glioma (7).
We present the case of a patient with glioblas-
toma progressing after surgery, radiotherapy, and 
first-line nitrosourea-based chemotherapy, where 
administration of the chemotherapy with edote-
carin gave a very promising result.
Case report
In October 2003, an 18-year-old girl experienced 
occasional headaches localized in the occipital re-
gion, short periodical loss of vision in both eyes, 
flashes, flashing lights, and intolerance to odors. 
The patient’s medical history was unremarkable. 
One month later, she was hospitalized in the 
Department of Neurology for diagnostic evalu-
ation. Ophthalmic examination showed papill-
edema in both eyes. The neurological examina-
tion showed no abnormalities except for grade 
2 decreased vision in both eyes, according to Na-
tional Cancer Institute Common Terminolo-
gy Criteria for Adverse Events (CTCAE), ver-
sion 3.0 (8). Magnetic resonance imaging (MRI) 
of the brain showed a unilateral supratentorial 
round mass of 2.7 cm in (largest) diameter in the 
right parietal-occipital region. After a stereotactic 
biopsy in November 2003, anaplastic oligoastro-
cytoma grade 3 according to the World Health 
Organization (WHO) classification of brain tu-
mors (9) was diagnosed. In December 2003, the 
patient underwent an osteoplastic craniotomy 
with reduction in tumor mass as a final result. 
After surgery, neurological status was unchanged, 
and control brain MRI was not done. In January 
2004, external radiotherapy was started. The pa-
tient received a planned tumor dose of 60 Gy in 
30 fractions. Chemotherapy treatment with lo-
mustine (1(2-chloroethyl)-3-cyclohexyl-1-nitro-
sourea, CCNU) was started in February 2004. 
She received only one of 6 planned cycles of che-
motherapy due to neurological and radiologi-
cal disease progression. During radiotherapy she 
started with anticonvulsive (methylphenobarbi-
tone) and antiedematous therapy (prednisolone). 
A control brain MRI in March 2004 showed en-
hancing supratentorial round mass of 5 × 4 cm in 
size in the right parietal-occipital region. A sec-
ond stereotactic biopsy was performed in April 
2004 and pathohistological findings showed a 
multiform glioblastoma. After the biopsy, a con-
trol brain MRI in May 2004 was performed and 
the largest tumor size was 5.9 × 2.9 cm in the 
transversal line.
The patient came to the Center of Oncology, 
Split University Hospital, in May 2004 due to 
neurological progression. On admission, her Kar-
nofsky performance status was 90%. Her neu-
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rological findings were as follows: grade 2 head-
aches, grade 1 weakness in the left arm, grade 1 
weakness in the left leg, grade 2 decreased vision, 
and grade 1 memory impairment. Psychological 
exam showed anxiousness and uneasiness. Labo-
ratory results of blood hematology and chemistry 
were within reference ranges.
Due to clinically and radiologically confirmed 
disease progression, the patient was enrolled in 
the EDOAGL-8725-001 study (A phase III, 
randomized, open-label study of IV edotecarin 
vs temozolomide or carmustine (BCNU) or lo-
mustine (CCNU) in patients with glioblastoma 
multiforme that has progressed/recurred after 
alkylator-based (neo) adjuvant chemotherapy). 
After the patient signed the informed consent 
form, she was randomized to receive monother-
apy with edotecarin. A central venous catheter 
was inserted. Chemotherapy with edotecarin 
was started in May 2004. Until October 2005 
the patient received 24 cycles of chemother-
apy with edotecarin in unchanged dose of 13 
mg/m2. Edotecarin was given in infusion over 
1 hour, once every 3 weeks. Thirty minutes be-
fore edotecarin infusion, a prophylaxis consist-
ing of 10 mg of ondansetron hydrochloride IV, 
1 mg lorazepam IV, and 20 mg of prednisolone 
IV was administered. During the next 4 days, 
the patient was given oral antiemetic therapy 
consisting of 8 mg of granisetron and 1 mg of lo-
razepam every 6 hours. Antiedematous and an-
ticonvulsive therapy with 10 mg of prednisone 
twice daily and methylphenobarbitone 200 mg 
daily, respectively, was not changed when treat-
ment with the study protocol started. After the 
introduction of a central venous catheter, pro-
phylactic anticoagulation therapy with warfarin 
(3 mg daily) was administered.
With every second cycle of chemotherapy (6 
weeks apart) a control brain MRI was done and 
the tumor response was evaluated by modified 
Response Evaluation Criteria in Solid Tumors 
(RECIST) (10). After 8 cycles of chemotherapy, 
clinical improvement was observed on neurolog-
ical examination, which was normal except for 
grade 1 decreased vision.
Partial radiological tumor response was 
achieved after the 16th cycle of chemotherapy, 
with a 62% reduction in size from the baseline. 
The best radiological tumor response was record-
ed after the 20th cycle of chemotherapy, with 
66.7% reduction in tumor size in comparison with 
the baseline MRI findings (Figure 1).
The patient has been using anticonvulsive 
and antiedematous therapy in unchanged dose. 
Although there were no major toxic effects that 
would require discontinuation of chemotherapy, 
there were some mild to moderate toxic effects 
present in the patient during the treatment. The 
severity and type of observed toxic effects accord-
Figure 1. Transverse magnetic resonance imaging (MRI) brain scans 
revealed the tumor mass in right parietal-occipital region in the 18-
year-old woman with glioblastoma multiforme. A. Largest size of tu-
mor mass at baseline, 5.9 × 2.9 cm. B. Largest size of tumor mass 
after 20 cycles of chemotherapy with edotecarin, 3.8 × 1.5 cm.
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ing to the National Cancer Institute Common 
Terminology Criteria for Adverse Events (CT-
CAE), version 3.0, were as follows: grade 2 head-
aches, grade 2 fatigue, grade 1 leucopenia, grade 1 
constipation, grade 1 vomiting, and bloody diar-
rhea (8).
In consensus with the patient, we are plan-
ning to continue with edotecarin chemotherapy, 
sponsored by Pfizer Pharmaceutical Company, 
until the disease progression or development of 
unacceptable toxicity.
Discussion
Despite numerous investigations, the role and 
time of application of chemotherapy in patients 
with glioblastoma has not been clearly defined. 
Statistically significant improvement in survival 
was achieved with radiotherapy treatment after 
surgical resection (11), whereas studies investi-
gating chemotherapy after surgical resection fol-
lowed by radiotherapy did not show a statisti-
cally significant survival benefit (12). However, 
meta-analysis of the results of 12 studies detect-
ed small but statistically significant survival bene-
fit achieved by chemotherapy after radiotherapy, 
with a 2-month increase in survival median (13). 
Although polychemotherapy is usually adminis-
tered, it did not show statistically significant ben-
efit in comparison with monochemotherapy in 
the treatment of patients with glioblastoma (14). 
The most commonly used agents are nitrosourea 
derivatives. Recently, promising results have been 
achieved with temozolomide in concomitant 
chemoradiotherapy setting followed by adjuvant 
chemotherapy (2).
Beside previously known prognostic factors 
(age, extent of surgical resection, mental status, 
and Karnofsky performance status), it is impor-
tant to emphasize the molecular characteristics 
of the tumor, which determined existence and 
expression of the chemotherapy benefit (3).
Chemotherapy achieves even less effects in 
patients with recurrent glioblastoma. Survival of 
such patients rarely exceeds 6 months. The aim 
of the treatment is palliation with improvement 
in quality of life. Temozolomide is the most rec-
ognized agent for the treatment of this patient 
population, because it has modest clinical effica-
cy, acceptable safety profile, and measurable im-
provement in quality of life (4,5).
Edotecarin, after promising results in the pre-
clinical and early clinical studies, has been evalu-
ated in the phase III trial. Phase III study was ter-
minated early due to the results of the interim 
analysis that showed no statistically significant 
benefit obtained with edotecarin. Nevertheless, 
we decided to present success of chemotherapy 
with edotecarin in a patient with nitrosourea re-
fractory disease enrolled in the study. There were 
also 3 more patients enrolled in this phase III tri-
al at our institution. Two of them have received 
edotecarin. One had disease progression after the 
first cycle. In the second patient the therapy was 
discontinued after the second cycle due to gran-
ulocytopenia grade IV and seizures grade III, de-
spite stable disease according to the modified 
RECIST criteria (10). During a one-year follow-
up period, this patient was without neurological 
worsening and with partial disease regression ac-
cording to modified RECIST criteria (10). The 
third patient received temozolomide and her 
best tumor response was stable disease; however, 
after 8 cycles disease progression occurred.
Knowing the nature of the glioblastoma and 
its chemoresistance, we believe that every patient 
should be approached individually and treated 
with the best available anticancer modalities. No 
drug should be dismissed as inactive for all pa-
tients and better tests of in vivo or in vitro che-
mosensitivity should be developed to help us se-
lect the best drug or drug combination in the 
treatment of such deadly disease.
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